Demannose

Demannose

SCHEMBL3293375

O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=S(=O)([O-])[O-].[Mg+2]

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Demannose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TDP1 Q9NUW8 1/20 0.42
TP53 P04637 1/20 0.39
PDE4A P27815 1/20 0.38
USP2 O75604 1/20 0.35
SLCO1B1 Q9Y6L6 1/20 0.35
AKR1B1 P15121 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MGAM O43451 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Demannose SCHEMBL27640995 1.00 LMNA (0.44) LMNAL3MBTL1TDP1TP53PDE4A
Demannose SCHEMBL28134059 0.96 LMNA (0.44) LMNAL3MBTL1TDP1TP53PDE4A
Demannose SCHEMBL870938 0.96 LMNA (0.44) LMNAL3MBTL1TDP1TP53PDE4A
Demannose SCHEMBL28107748 0.96 LMNA (0.44) LMNAL3MBTL1TDP1TP53PDE4A
Demannose SCHEMBL870939 0.96 LMNA (0.44) LMNAL3MBTL1TDP1TP53PDE4A
Demannose SCHEMBL28415027 0.96 LMNA (0.44) LMNAL3MBTL1TDP1TP53PDE4A
Demannose SCHEMBL29777539 0.96 LMNA (0.44) LMNAL3MBTL1TDP1TP53PDE4A
Demannose SCHEMBL27745349 0.96 LMNA (0.44) LMNAL3MBTL1TDP1TP53PDE4A
Demannose SCHEMBL21403375 0.96 LMNA (0.44) LMNAL3MBTL1TDP1TP53PDE4A
Demannose SCHEMBL27616123 0.92 LMNA (0.41) LMNAL3MBTL1TDP1TP53PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117143947-A Induced fermentation process for producing collagen tripeptide by escherichia coli fermentation 北京诺尼瑞生物科技有限责任公司 2023-12-01 CN claimed
CN-219376340-U Filter equipment is used in preparation of magnesium sulfate glucose injection 武汉博志宇恒科技有限公司 2023-07-21 CN claimed
CN-114774496-B Method for preparing GLP-1 analogue through high-density fermentation 北京惠之衡生物科技有限公司 2022-10-04 CN claimed
CN-117143947-A Induced fermentation process for producing collagen tripeptide by escherichia coli fermentation 北京诺尼瑞生物科技有限责任公司 2023-12-01 CN disclosed
CN-219376340-U Filter equipment is used in preparation of magnesium sulfate glucose injection 武汉博志宇恒科技有限公司 2023-07-21 CN disclosed
CN-219376340-U Filter equipment is used in preparation of magnesium sulfate glucose injection 武汉博志宇恒科技有限公司 2023-07-21 CN disclosed
CN-219376340-U Filter equipment is used in preparation of magnesium sulfate glucose injection 武汉博志宇恒科技有限公司 2023-07-21 CN disclosed
CN-114774496-B Method for preparing GLP-1 analogue through high-density fermentation 北京惠之衡生物科技有限公司 2022-10-04 CN disclosed
CN-114774496-A Method for preparing GLP-1 analogue through high-density fermentation 北京惠之衡生物科技有限公司 2022-07-22 CN disclosed
US-7732587-B2 Nucleic acids encoding truncated soluble tumor necrosis factor AMGEN INC. (US) 2010-06-08 US disclosed
US-7381545-B2 Method for controlling metallophosphate precipitation in high cell density fermentations AMGEN INC. (US) 2008-06-03 US disclosed
US-7118884-B1 Method for controlling metallophosphate precipitation in high cell density fermentations AMGEN INC. (US) 2006-10-10 US disclosed
US-6989147-B2 Truncated soluble tumor necrosis factor type-I and type-II receptors AMGEN INC. (US) 2006-01-24 US disclosed
US-20050250696-A1 Truncated soluble tumor necrosis factor type-I and type-II receptors FISHER ERIC F 2005-11-10 US disclosed
US-20030054439-A1 Truncated soluble tumor necrosis factor type-I and type-II receptors AMGEN INC. 2003-03-20 US disclosed
EP-0755438-B1 METHOD FOR CONTROLLING METALLOPHOSPHATE PRECIPITATION IN HIGH CELL DENSITY FERMENTATIONS AMGEN INC (US) 2001-02-14 EP disclosed
EP-0914431-A2 TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS AMGEN INC. (US) 1999-05-12 EP disclosed
WO-1998001555-A2 TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS AMGEN INC. (US) 1998-01-15 WO disclosed
EP-0755438-A1 METHOD FOR CONTROLLING METALLOPHOSPHATE PRECIPITATION IN HIGH CELL DENSITY FERMENTATIONS AMGEN INC. (US) 1997-01-29 EP disclosed
WO-1995029986-A1 METHOD FOR CONTROLLING METALLOPHOSPHATE PRECIPITATION IN HIGH CELL DENSITY FERMENTATIONS AMGEN INC. (US) 1995-11-09 WO disclosed